Ambys Medicines Inc. interim CEO Jeff Tong said the firm's unusual combination of the $60 million series A financing with a deal enlisting Takeda Pharmaceutical Co. Ltd. to the tune of $80 million up front came about because venture backer Third Rock, where Tong is a partner, "wanted to make sure that by doing the deal we weren't going to hamper the growth of the company."